(Q33764666)

29 July 2017

1 reference

title

Advances in vaccine adjuvants (English)

1 reference

29 July 2017

1 reference

Singh M

1

1 reference

PubMed ID

10545912

29 July 2017

O'Hagan D

series ordinal

2

1 reference

29 July 2017

1 November 1999

1 reference

29 July 2017

1 reference

29 July 2017

17

1 reference

29 July 2017

11

1 reference

29 July 2017

1075-1081

1 reference

https://scigraph.springernature.com/pub.10.1038/15058

29 July 2017

0 references

cites work

Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines

1 reference

7 January 2021

Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids

1 reference

7 January 2021

Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies

1 reference

7 January 2021

The role of IL-10 in crossregulation of TH1 and TH2 responses

1 reference

7 January 2021

Human TH1 and TH2 subsets: doubt no more

1 reference

7 January 2021

Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production

1 reference

7 January 2021

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

1 reference

7 January 2021

Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide

1 reference

7 January 2021

Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling

1 reference

7 January 2021

Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity

1 reference

7 January 2021

Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system

1 reference

7 January 2021

Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function

1 reference

7 January 2021

Action of Saponin on Biological Cell Membranes

1 reference

7 January 2021

QS-21: a water-soluble triterpene glycoside adjuvant

1 reference

7 January 2021

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

1 reference

7 January 2021

Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes

1 reference

7 January 2021

CpG motifs in bacterial DNA trigger direct B-cell activation

1 reference

7 January 2021

Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells.

1 reference

7 January 2021

DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen

1 reference

7 January 2021

CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus

1 reference

7 January 2021

CpG motifs as immune adjuvants

1 reference

7 January 2021

Use of cellular and cytokine adjuvants in the immunotherapy of cancer

1 reference

7 January 2021

An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity

1 reference

7 January 2021

Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59.

1 reference

7 January 2021

Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles

1 reference

7 January 2021

MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice

1 reference

7 January 2021

The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice

1 reference

7 January 2021

MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates

1 reference

7 January 2021

MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine

1 reference

7 January 2021

Dendritic cells internalize vaccine adjuvant after intramuscular injection

1 reference

7 January 2021

Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers

1 reference

7 January 2021

A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]

1 reference

7 January 2021

Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use.

1 reference

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

7 January 2021

Immunological adjuvants: a role for liposomes

1 reference

7 January 2021

Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

1 reference

7 January 2021

Targeting immune response induction with cochleate and liposome-based vaccines

1 reference

7 January 2021

ISCOMs and other saponin based adjuvants

1 reference

7 January 2021

Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines

1 reference

7 January 2021

Biodegradable microspheres in drug delivery

1 reference

7 January 2021

Improving protein therapeutics with sustained-release formulations

1 reference

7 January 2021

Controlled release microparticles for vaccine development

1 reference

7 January 2021

Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

1 reference

7 January 2021

Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles

1 reference

7 January 2021

Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells.

1 reference

7 January 2021

Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity

1 reference

7 January 2021

Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses

1 reference

7 January 2021

Development of adjuvant-active nonionic block copolymers

1 reference

7 January 2021

Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine.

1 reference

7 January 2021

Synthesis and assembly of hepatitis B virus surface antigen particles in yeast

1 reference

7 January 2021

Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens

1 reference

7 January 2021

A protein particle vaccine containing multiple malaria epitopes.

1 reference

7 January 2021

Optimism over vaccines administered via mucosal surfaces.

1 reference

7 January 2021

Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles.

1 reference

7 January 2021

Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection

1 reference

7 January 2021

Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles

1 reference

7 January 2021

Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection

1 reference

7 January 2021

Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres

1 reference

7 January 2021

Protection against vaginal SIV transmission with microencapsulated vaccine

1 reference

7 January 2021

Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses

1 reference

7 January 2021

Biologically erodable microspheres as potential oral drug delivery systems

1 reference

7 January 2021

Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration.

1 reference

7 January 2021

PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization

1 reference

7 January 2021

Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants

1 reference

7 January 2021

Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity

1 reference

7 January 2021

Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant

1 reference

7 January 2021

Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity

1 reference

7 January 2021

Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant.

1 reference

7 January 2021

Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins

1 reference

7 January 2021

Skin immunization made possible by cholera toxin

1 reference

7 January 2021

Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes

1 reference

7 January 2021

Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant

1 reference

7 January 2021

Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2

1 reference

7 January 2021

Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection

1 reference

7 January 2021

Oral tolerance: immune mechanisms and treatment of autoimmune diseases

1 reference

7 January 2021

Microparticles and polymers for the mucosal delivery of vaccines

1 reference

7 January 2021

Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins

1 reference

7 January 2021

Lectin-bearing polymerized liposomes as potential oral vaccine carriers

1 reference

7 January 2021

Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo

1 reference

7 January 2021

Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat

1 reference

7 January 2021

HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-gamma antibody

1 reference

7 January 2021

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

1 reference

7 January 2021

CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation

1 reference

7 January 2021

Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein

1 reference

7 January 2021

Identifiers

DOI

10.1038/15058

1 reference

29 July 2017

1 reference

PubMed ID

10545912